ERBB2 and breast carcinoma: Other studies evaluating the role of miRNAs to indicate treatment response has shown some promising results (as outlined in Table 1 and Table 2): Jung et al. implicate miR-210 as a predictive biomarker of response to trastzumab in HER2-positive breast cancer patients [42], with upregulation being associated with resistance to such therapies, while Ichikawa et al. also demonstrate the utility of miR-26a and miR-30b in mediating the impact of anti-HER2 therapies [60].